{"analyses":[{"ciLowerLimit":"1.01","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.35","estimateComment":"Reference level = Hormone Therapy + Radiation Therapy","groupDescription":"Null hypothesis: 8-year OS rate of 60% radiation therapy (RT) alone vs. 67% with hormone therapy. The study was designed with 90% power to detect a 7-percentage- point absolute difference in the 8-year survival rate, with the use of a one-sided log-rank test at the 0.025 significance level, requiring 1980 patients and 716 deaths for definitive analysis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0309","paramType":"Hazard Ratio (HR)","paramValue":"1.17","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.3","upperLimit":"65.3","value":"61.9"},{"groupId":"OG001","lowerLimit":"53.2","upperLimit":"60.2","value":"56.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"987"},{"groupId":"OG001","value":"992"}],"units":"Participants"}],"description":"Overall survival (OS) was calculated from randomization to the date of death from any cause and overall survival rates were estimated by the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.","id":"OG000","title":"Hormone Therapy + Radiation Therapy"},{"description":"Radiation therapy alone","id":"OG001","title":"Radiation Therapy Alone"}],"paramType":"NUMBER","populationDescription":"All eligible patients.","reportingStatus":"POSTED","timeFrame":"From date of randomization to 10 years","title":"Overall Survival Rate (10-year)","type":"PRIMARY","unitOfMeasure":"percentage of patients"}